Evidence map›Paper›PMID 26662632›Full record

Trial reportInternational journal of clinical oncology2016

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.

Hideaki Yahata, Hiroaki Kobayashi, Kenzo Sonoda, Mototsugu Shimokawa, Tatsuhiro Ohgami, Toshiaki Saito, Shinji Ogawa, Kunihiro Sakai, Akimasa Ichinoe, Yousuke Ueoka and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 9 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 9 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Global inequitable distribution of seminal studies of chemotherapy-induced nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  17. Postoperative nausea and vomiting as a predictor of chemotherapy-induced nausea and vomiting in gynecologic cancer: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Hideaki YahataDepartment of Obstetrics and Gynecology, Kyushu University Hospital, Fukuoka, Japan.
Hiroaki KobayashiDepartment of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University Hospital, Kagoshima, Japan. hirokoba@m2.kufm.kagoshima-u.ac.jp.
Kenzo SonodaDepartment of Obstetrics and Gynecology, Kyushu University Hospital, Fukuoka, Japan.
Mototsugu ShimokawaCenter of Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan.
Tatsuhiro OhgamiDepartment of Obstetrics and Gynecology, Miyazaki Prefectural Hospital, Miyazaki, Japan.
Toshiaki SaitoGynecology Service, National Kyushu Cancer Center, Fukuoka, Japan.
Shinji OgawaDepartment of Obstetrics and Gynecology, Kyushu Hospital, Kitakyushu, Japan.
Kunihiro SakaiDepartment of Obstetrics and Gynecology, Saiseikai Fukuoka Hospital, Fukuoka, Japan.
Akimasa IchinoeDepartment of Obstetrics and Gynecology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Yousuke UeokaDepartment of Obstetrics and Gynecology, Hamanomachi Hospital, Fukuoka, Japan.
Yasuyuki HasuoDepartment of Obstetrics and Gynecology, National Kyushu Medical Center, Fukuoka, Japan.
Makoto NishidaDepartment of Obstetrics and Gynecology, Fukuoka Red Cross Hospital, Fukuoka, Japan.
Satohiro MasudaDepartment of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
Kiyoko KatoDepartment of Obstetrics and Gynecology, Kyushu University Hospital, Fukuoka, Japan.
Kyushu University Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPHamanomachi Hospital · JPJapanese Red Cross Fukuoka Hospital · JPKagoshima University Hospital · JPKitakyushu Municipal Medical Center · JPKyushu Hospital · JPMiyazaki Prefectural Hospital · JPNational Kyushu Medical Center · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubstance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model. Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR. While aprepitant has a prophylactic effect against vomiting caused by high-dose cisplatin, the benefits of aprepitant have not been clearly demonstrated in patients receiving paclitaxel and carboplatin (TC) combination chemotherapy.

methodsWe conducted a multicenter, placebo-controlled, double-blind, randomized study in Japanese patients with gynecologic cancer who received TC combination chemotherapy. Patients received aprepitant or placebo together with both a 5-HT3 receptor antagonist and dexamethasone prior to chemotherapy. The primary endpoint was the proportion of patients with HSR, and the secondary endpoints were the proportion of patients with "no vomiting", "no significant nausea", and complete response, respectively.

resultsOf the 324 randomized patients, 297 (151 in the aprepitant group; 146 in the placebo group) were evaluated. The percentage of patients with HSR (9.2 vs. 7.5 %, respectively; P = 0.339) was not significantly different between the groups. The percentage of "no vomiting" patients (78.2 vs. 54.8 %; P < 0.0001), "no significant nausea" patients (85.4 vs. 74.7 %; P = 0.014), and patients showing complete response (61.6 vs. 47.3 %, P = 0.0073) was significantly higher in the aprepitant group than in the placebo group.

conclusionThe administration of aprepitant did not have a prophylactic effect on the HSR but was effective in reducing nausea and vomiting in gynecologic cancer patients receiving TC combination chemotherapy.

Indexed as

AdultAgedAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsAprepitantCarboplatinDexamethasoneDouble-Blind MethodDrug HypersensitivityDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansMiddle AgedMorpholinesNauseaAntiemeticsAprepitantCarboplatinDexamethasoneMorpholinesPaclitaxelSerotonin 5-HT3 Receptor AntagonistsAprepitantCINVGynecologic cancerHypersensitivity reactionMEC regimen

Identifiers

PMID26662632
OpenAlexW2193998544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.